Abstract #0369
T1 based surrogate MRI marker for hyperthermia-induced release of doxorubicin from thermosensitive liposomes in solid tumors
Michael Peller 1 , Linus Willerding 1,2 , Simone Limmer 2 , Martin Hossann 2,3 , Olaf Dietrich 1 , Michael Ingrisch 1 , Lars Lindner 2,3 , and Maximilian F. Reiser 1
1
Department of Clinical Radiology, University
Hospital of Munich, Munich, Germany,
2
Department
of Internal Medicine III, University Hospital of Munich,
Munich, Germany,
3
CCG
Tumor Therapy through Hyperthermia, Helmholtz Zentrum
Mnchen, German Research Center for Environmental
Health, Munich, Germany
Effectiveness of anti-cancer drugs can be improved by
tumor-targeting. Using thermosensitive liposomes such
targeting is realized by tumor specific hyperthermia and
visualization by loading the TSL with MRI-contrast
agents. Purpose of this in vivo study is to test
T1-based assessment of hyperthermia induced doxorubicin
release in tumors using a mixture of thermosensitive
liposomes loaded with a clinically approved contrast
agent or doxorubicin, respectively. Assessment of
doxorubicin accumulated in heterogeneous tumors tissue
seems feasible. This was the first time that a mixture
of thermosensitive liposomes loaded either with contrast
agent or doxorubicin has been investigated.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Click here for more information on becoming a member.
